NCT00629616View on ClinicalTrials.gov

Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2015

Study Completion Date

April 30, 2018

Conditions
Breast Cancer
Interventions
DRUG

anastrozole

1 mg/day for either 4 months or 6 months depending on the clinical evaluation

DRUG

fulvestrant

500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation

Trial Locations (6)

35042

Centre Eugene Marquis, Rennes

63011

Centre Jean Perrin, Clermont-Ferrand

75248

Institut Curie Hopital, Paris

87042

Hopital Dupuytren, Limoges

92210

Centre Rene Huguenin, Saint-Cloud

F-94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

UNICANCER

OTHER

NCT00629616 - Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer | Biotech Hunter | Biotech Hunter